Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments

Daniel M. Beswick, Stacey T. Gray, Timothy Smith

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic rhinosinusitis (CRS) is an inflammatory sinonasal condition with multiple etiologic factors that is associated with a vast economic cost. Treatment is most frequently pharmacologic and has centered on agents that ameliorate inflammation, decrease bacterial or pathogen load, and facilitate egress of mucus or purulence from the sinonasal cavity. Nasal saline irrigations, topical nasal steroids, certain antibiotics, and systemic steroids have shown some efficacy in the management of CRS. Recently, biologic therapeutics that target specific inflammatory pathways associated with subsets of CRS have been developed and evaluated. Early data evaluating these biologic treatments suggest a potential role in treating a subset of CRS with refractory, poorly controlled disease. Additional studies are necessary to identify which patients would benefit most from biologic therapies and to assess the cost of these therapies compared with the benefit they provide. This review describes the pathophysiology of CRS and summarizes both established and novel biologic pharmacologic treatments.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalDrugs
DOIs
StateAccepted/In press - Aug 29 2017

Fingerprint

Pharmacology
Steroids
Nasal Lavage
Therapeutics
Costs and Cost Analysis
Biological Therapy
Mucus
Nose
Economics
Anti-Bacterial Agents
Inflammation

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacological Management of Chronic Rhinosinusitis : Current and Evolving Treatments. / Beswick, Daniel M.; Gray, Stacey T.; Smith, Timothy.

In: Drugs, 29.08.2017, p. 1-9.

Research output: Contribution to journalArticle

@article{a612eeed4fdd4f259ace40e3eb664e31,
title = "Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments",
abstract = "Chronic rhinosinusitis (CRS) is an inflammatory sinonasal condition with multiple etiologic factors that is associated with a vast economic cost. Treatment is most frequently pharmacologic and has centered on agents that ameliorate inflammation, decrease bacterial or pathogen load, and facilitate egress of mucus or purulence from the sinonasal cavity. Nasal saline irrigations, topical nasal steroids, certain antibiotics, and systemic steroids have shown some efficacy in the management of CRS. Recently, biologic therapeutics that target specific inflammatory pathways associated with subsets of CRS have been developed and evaluated. Early data evaluating these biologic treatments suggest a potential role in treating a subset of CRS with refractory, poorly controlled disease. Additional studies are necessary to identify which patients would benefit most from biologic therapies and to assess the cost of these therapies compared with the benefit they provide. This review describes the pathophysiology of CRS and summarizes both established and novel biologic pharmacologic treatments.",
author = "Beswick, {Daniel M.} and Gray, {Stacey T.} and Timothy Smith",
year = "2017",
month = "8",
day = "29",
doi = "10.1007/s40265-017-0803-4",
language = "English (US)",
pages = "1--9",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Pharmacological Management of Chronic Rhinosinusitis

T2 - Current and Evolving Treatments

AU - Beswick, Daniel M.

AU - Gray, Stacey T.

AU - Smith, Timothy

PY - 2017/8/29

Y1 - 2017/8/29

N2 - Chronic rhinosinusitis (CRS) is an inflammatory sinonasal condition with multiple etiologic factors that is associated with a vast economic cost. Treatment is most frequently pharmacologic and has centered on agents that ameliorate inflammation, decrease bacterial or pathogen load, and facilitate egress of mucus or purulence from the sinonasal cavity. Nasal saline irrigations, topical nasal steroids, certain antibiotics, and systemic steroids have shown some efficacy in the management of CRS. Recently, biologic therapeutics that target specific inflammatory pathways associated with subsets of CRS have been developed and evaluated. Early data evaluating these biologic treatments suggest a potential role in treating a subset of CRS with refractory, poorly controlled disease. Additional studies are necessary to identify which patients would benefit most from biologic therapies and to assess the cost of these therapies compared with the benefit they provide. This review describes the pathophysiology of CRS and summarizes both established and novel biologic pharmacologic treatments.

AB - Chronic rhinosinusitis (CRS) is an inflammatory sinonasal condition with multiple etiologic factors that is associated with a vast economic cost. Treatment is most frequently pharmacologic and has centered on agents that ameliorate inflammation, decrease bacterial or pathogen load, and facilitate egress of mucus or purulence from the sinonasal cavity. Nasal saline irrigations, topical nasal steroids, certain antibiotics, and systemic steroids have shown some efficacy in the management of CRS. Recently, biologic therapeutics that target specific inflammatory pathways associated with subsets of CRS have been developed and evaluated. Early data evaluating these biologic treatments suggest a potential role in treating a subset of CRS with refractory, poorly controlled disease. Additional studies are necessary to identify which patients would benefit most from biologic therapies and to assess the cost of these therapies compared with the benefit they provide. This review describes the pathophysiology of CRS and summarizes both established and novel biologic pharmacologic treatments.

UR - http://www.scopus.com/inward/record.url?scp=85028769749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028769749&partnerID=8YFLogxK

U2 - 10.1007/s40265-017-0803-4

DO - 10.1007/s40265-017-0803-4

M3 - Article

C2 - 28853058

AN - SCOPUS:85028769749

SP - 1

EP - 9

JO - Drugs

JF - Drugs

SN - 0012-6667

ER -